A Study of Sacituzumab Govitecan (IMMU-132) in Platinum-resistant Ovarian Cancer Patients
Status:
Recruiting
Trial end date:
2027-11-01
Target enrollment:
Participant gender:
Summary
This is a non-randomized Phase 2 study of sacituzumab govitecan (IMMU-132) in subjects with
recurrent or persistent platinum-resistant epithelial ovarian, fallopian tube, or primary
peritoneal cancers.